Form 4: ImmunityBio Director Sells Shares, Exercises RSUs

ImmunityBio Director Barry J. Simon reported multiple transactions including sales of common stock and the vesting and subsequent tax-related disposition of restricted stock units.

Summary

• Director Barry J. Simon reported transactions executed under a Rule 10b5-1 trading plan adopted on September 4, 2024.
• On February 20, 2026, 10,000 shares of common stock were sold at a price of $9.25 per share.
• On February 22, 2026, 15,243 Restricted Stock Units (RSUs) vested, converting into common stock.
• Concurrently on February 22, 2026, 6,026 shares were disposed of at $8.7 per share to cover tax withholding obligations related to the RSU vesting.
• On February 23, 2026, an additional 165,000 shares of common stock were sold at a weighted average price of $10.2491 per share, with prices ranging from $9.89 to $10.635.
• Following these transactions, the director's beneficial ownership of ImmunityBio, Inc. common stock stands at 2,925,821 shares.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal given the substantial volume of shares sold by a director, which could be interpreted as a move to reduce exposure, despite the transactions being pre-planned.

Positives

• The vesting of 15,243 Restricted Stock Units (RSUs) represents the fulfillment of equity compensation for the director, indicating continued alignment with company performance.

Negatives

• Director Barry J. Simon sold a total of 175,000 shares of common stock over two days, which represents a significant reduction in his direct holdings.

Risks

• Significant insider selling by a director, even if pre-planned under a Rule 10b5-1 plan, could be interpreted negatively by the market, potentially signaling a lack of confidence or a move to diversify holdings.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider selling, even when pre-planned via a 10b5-1 plan, is often scrutinized by investors for potential signals regarding management's confidence in the company's near-term prospects. In the biotechnology sector, such transactions can sometimes coincide with clinical trial milestones or regulatory decisions, though this filing provides no such context.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all industries.
• The use of a Rule 10b5-1 trading plan is a common practice among executives to mitigate accusations of insider trading by pre-scheduling sales.
• Without specific company performance data, direct comparisons to industry peers like Moderna (MRNA) or BioNTech (BNTX) regarding executive compensation or stock sales are not directly applicable from this filing alone, as this is a disclosure of individual transactions, not a company performance report.

Stakeholder Impact

• Shareholders: Potential negative sentiment due to director selling, which could put downward pressure on the stock price.

Key Dates

Recommendation

The director's sales, while significant, were executed under a pre-arranged Rule 10b5-1 trading plan, suggesting a planned diversification or liquidity event rather than an immediate reaction to negative company news. Without additional fundamental information or a change in company outlook, a 'hold' recommendation is appropriate, advising investors to monitor future filings and company performance.

Keywords

ImmunityBio, IBRX, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, Equity Compensation, Director Transactions, Barry J. Simon, Rule 10b5-1